EP3900717C0 - Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen - Google Patents

Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen

Info

Publication number
EP3900717C0
EP3900717C0 EP21169334.6A EP21169334A EP3900717C0 EP 3900717 C0 EP3900717 C0 EP 3900717C0 EP 21169334 A EP21169334 A EP 21169334A EP 3900717 C0 EP3900717 C0 EP 3900717C0
Authority
EP
European Patent Office
Prior art keywords
vidofludimus
prevention
treatment
virus diseases
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP21169334.6A
Other languages
English (en)
French (fr)
Other versions
EP3900717B1 (de
EP3900717A1 (de
Inventor
Manfred Gröppel
Daniel Vitt
Hella Kohlhof
Andreas Mühler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunic AG
Original Assignee
Immunic AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunic AG filed Critical Immunic AG
Priority to EP24213073.0A priority Critical patent/EP4487870A3/de
Publication of EP3900717A1 publication Critical patent/EP3900717A1/de
Application granted granted Critical
Publication of EP3900717B1 publication Critical patent/EP3900717B1/de
Publication of EP3900717C0 publication Critical patent/EP3900717C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP21169334.6A 2020-04-21 2021-04-20 Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen Active EP3900717B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP24213073.0A EP4487870A3 (de) 2020-04-21 2021-04-20 Vidofludimus zur verwendung bei der behandlung oder prävention von viruserkrankungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170729 2020-04-21
EP20184031 2020-07-03
EP21164552 2021-03-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP24213073.0A Division EP4487870A3 (de) 2020-04-21 2021-04-20 Vidofludimus zur verwendung bei der behandlung oder prävention von viruserkrankungen

Publications (3)

Publication Number Publication Date
EP3900717A1 EP3900717A1 (de) 2021-10-27
EP3900717B1 EP3900717B1 (de) 2024-11-20
EP3900717C0 true EP3900717C0 (de) 2024-11-20

Family

ID=75497947

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21169334.6A Active EP3900717B1 (de) 2020-04-21 2021-04-20 Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen
EP24213073.0A Pending EP4487870A3 (de) 2020-04-21 2021-04-20 Vidofludimus zur verwendung bei der behandlung oder prävention von viruserkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP24213073.0A Pending EP4487870A3 (de) 2020-04-21 2021-04-20 Vidofludimus zur verwendung bei der behandlung oder prävention von viruserkrankungen

Country Status (11)

Country Link
US (2) US11376232B2 (de)
EP (2) EP3900717B1 (de)
JP (1) JP2023522245A (de)
KR (1) KR20230004636A (de)
CN (1) CN115867268A (de)
AU (1) AU2021260040A1 (de)
CA (1) CA3176008A1 (de)
ES (1) ES3010487T3 (de)
MA (1) MA53193A (de)
TW (1) TWI791212B (de)
WO (1) WO2021214033A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023522245A (ja) * 2020-04-21 2023-05-29 イミュニック アクチェンゲゼルシャフト ウイルス性疾患の治療又は予防において使用するためのビドフルジムス
EP4313150A1 (de) 2021-03-26 2024-02-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Kombination von pyrimidinbiosynthesehemmern zur verwendung bei der behandlung von virusinfektionen
US11724077B2 (en) * 2021-07-28 2023-08-15 Subhash Dhawan Therapeutic swabs for treating upper respiratory infections
JPWO2023224029A1 (de) * 2022-05-16 2023-11-23
CN116003508B (zh) * 2023-01-20 2025-07-08 厦门蔚扬药业有限公司 一种含氰基的硒代丁内酰胺化合物及其制备方法和用途
WO2025036938A1 (en) 2023-08-15 2025-02-20 Immunic Ag Oral pharmaceutical dosage form providing immediate release of vidofludimus
KR102686544B1 (ko) 2023-12-04 2024-07-19 대한민국 Bay-2402234을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물
WO2025215126A1 (en) 2024-04-12 2025-10-16 Immunic Ag Synthesis of vidofludimus and its calcium salt

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50121428A (de) 1974-03-12 1975-09-23
NL186239B (nl) 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
TWI530286B (zh) * 2009-05-04 2016-04-21 帕納特斯製藥格斯有限公司 作為抑制病毒化合物之抗發炎劑
UA108760C2 (uk) * 2010-07-01 2015-06-10 Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
JP5894741B2 (ja) 2011-03-22 2016-03-30 リケンテクノス株式会社 傷付き防止フィルム
WO2015154820A1 (en) 2014-04-11 2015-10-15 Panoptes Pharma Gmbh Anti-inflammatory agents as virostatic compounds
MX2020005360A (es) 2017-11-23 2020-08-13 Immunic Ag Compuestos y regimen de dosificacion para usarse en la prevencion o tratamiento de enfermedades inflamatorias cronicas y/o autoinmunes.
RS66222B1 (sr) 2017-12-07 2024-12-31 Univ Emory N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim
IL277326B2 (en) 2018-03-16 2024-03-01 Immunic Ag Calcium salt polymorph inhibitors of dihydroorotate dehydrogenase and processes for preparing same
US20220280513A1 (en) 2019-07-18 2022-09-08 The Board Of Trustees Of The Leland Stanford Junior University Enhancing the antiviral efficacy of rna virus inhibition by combination with modulators of pyrimidine metabolism
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP3892268B1 (de) * 2020-04-10 2022-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung von vidofludimus zur behandlung von coronavirusinfektionen
JP2023522245A (ja) * 2020-04-21 2023-05-29 イミュニック アクチェンゲゼルシャフト ウイルス性疾患の治療又は予防において使用するためのビドフルジムス

Also Published As

Publication number Publication date
US11376232B2 (en) 2022-07-05
EP3900717B1 (de) 2024-11-20
EP3900717A1 (de) 2021-10-27
CN115867268A (zh) 2023-03-28
MA53193A (fr) 2021-10-27
TW202139987A (zh) 2021-11-01
CA3176008A1 (en) 2021-10-28
US20210322351A1 (en) 2021-10-21
KR20230004636A (ko) 2023-01-06
ES3010487T3 (en) 2025-04-03
TWI791212B (zh) 2023-02-01
WO2021214033A1 (en) 2021-10-28
EP4487870A2 (de) 2025-01-08
US20220339132A1 (en) 2022-10-27
AU2021260040A1 (en) 2022-11-17
JP2023522245A (ja) 2023-05-29
EP4487870A3 (de) 2025-03-12
US12167994B2 (en) 2024-12-17

Similar Documents

Publication Publication Date Title
EP3900717C0 (de) Vidofludimus zur verwendung in der behandlung oder prävention von viruserkrankungen
EP3672594A4 (de) Kombinationsprodukt aus bcl-2-inhibitor und mdm2-inhibitor und verwendung davon zur prävention und/oder behandlung von krankheiten
EP3672639A4 (de) Kombinationsprodukt aus bcl-2-inhibitor oder bcl-2/bcl-xl-doppelinhibitor und btk-inhibitor und dessen verwendung zur prävention und/oder behandlung von krankheiten
EP4146633A4 (de) Zusammensetzung zur verwendung bei der behandlung von apol1-assoziierter erkrankung
EP3715349A4 (de) Bisdiazabicyclo-verbindung zur behandlung und/oder vorbeugung von hepatitis-virus-bedingten erkrankungen oder störungen
EP3827837A4 (de) Zusammensetzung zur vorbeugung oder behandlung von immunerkrankungen
EP4221838A4 (de) Snca-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von snca-assoziierten neurodegenerativen erkrankungen
EP3801477A4 (de) Verfahren und zusammensetzungen zur prävention oder behandlung von gewebekalzifizierung
EP4028021C0 (de) Verwendung von nmn zur prävention und/oder behandlung von schmerzen und entsprechende zusammensetzungen
EP4094754C0 (de) Zusammensetzungen zur behandlung und/oder prävention von proteinaggregationserkrankungen
EP4259153A4 (de) Neue verwendung von pyrrolopyridinderivaten zur prävention oder behandlung von entzündlichen erkrankungen
EP3927428C0 (de) Norketotifen zur behandlung von atemwegserkrankungen
EP4188390A4 (de) Atxn2-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit atxn2-assoziierten neurodegenerativen erkrankungen
EP3746067A4 (de) Zusammensetzungen und verfahren zur behandlung von lungenödem oder lungenentzündung
EP4438048A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von t-zell-bedingten erkrankungen
EP4000609A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenerkrankungen
EP4410308A4 (de) Zytotoxizitätsinduzierendes therapeutikum zur verwendung bei der behandlung von krebs
EP3766508A4 (de) Roharzneimittelzusammensetzung zur vorbeugung oder behandlung von atemwegserkrankungen
EP3932486A4 (de) Zusammensetzung zur behandlung von blutgerinnungs- und/oder komplementstörungen
EP3795175A4 (de) Verwendung zur vorbeugung und behandlung von mit myeloischen suppressorzellen verwandten krankheiten
EP4338267A4 (de) Varianten von sirt6 zur verwendung bei der vorbeugung und/oder behandlung altersbedingter erkrankungen
EP3801483A4 (de) Zusammensetzungen und verfahren zur behandlung von hormonell bedingten krankheiten oder störungen
EP4313010C0 (de) Verbindungen zur verwendung in der behandlung und prävention von covid-19
EP4570251A4 (de) Zusammensetzung zur behandlung oder prävention von nierenerkrankungen
EP4422416A4 (de) Buvinkonas sp zur verwendung bei der vorbeugung und behandlung von krankheiten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

B565 Issuance of search results under rule 164(2) epc

Effective date: 20210902

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220421

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062780

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230406

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230418

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20240326BHEP

Ipc: A61K 31/706 20060101ALI20240326BHEP

Ipc: A61P 31/14 20060101ALI20240326BHEP

Ipc: A61K 31/196 20060101AFI20240326BHEP

INTG Intention to grant announced

Effective date: 20240419

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20240730

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MUEHLER, ANDREAS

Inventor name: KOHLHOF, HELLA

Inventor name: VITT, DANIEL

Inventor name: GROEPPEL, MANFRED

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602021021971

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20241213

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20241223

P04 Withdrawal of opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_67103/2024

Effective date: 20241218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250320

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250220

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 5

Effective date: 20250424

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250423

Year of fee payment: 5

Ref country code: ES

Payment date: 20250519

Year of fee payment: 5

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250501

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241120

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20250428

Year of fee payment: 5

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20250821